384 related articles for article (PubMed ID: 26695512)
1. A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.
Bisacchi GS; Hale MR
Curr Med Chem; 2016; 23(6):520-77. PubMed ID: 26695512
[TBL] [Abstract][Full Text] [Related]
2. Recent advancements in the medicinal chemistry of bacterial type II topoisomerase inhibitors.
Jaswal S; Nehra B; Kumar S; Monga V
Bioorg Chem; 2020 Nov; 104():104266. PubMed ID: 33142421
[TBL] [Abstract][Full Text] [Related]
3. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Kassab AE; Gedawy EM
Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
[TBL] [Abstract][Full Text] [Related]
4. The quinolone family: from antibacterial to anticancer agents.
Sissi C; Palumbo M
Curr Med Chem Anticancer Agents; 2003 Nov; 3(6):439-50. PubMed ID: 14529452
[TBL] [Abstract][Full Text] [Related]
5. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
Naeem A; Badshah SL; Muska M; Ahmad N; Khan K
Molecules; 2016 Mar; 21(4):268. PubMed ID: 27043501
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
7. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.
Aldred KJ; Schwanz HA; Li G; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
ACS Chem Biol; 2013 Dec; 8(12):2660-8. PubMed ID: 24047414
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Pommier Y; Leo E; Zhang H; Marchand C
Chem Biol; 2010 May; 17(5):421-33. PubMed ID: 20534341
[TBL] [Abstract][Full Text] [Related]
9. Towards anticancer fluoroquinolones: A review article.
Abdel-Aal MAA; Abdel-Aziz SA; Shaykoon MSA; Abuo-Rahma GEA
Arch Pharm (Weinheim); 2019 Jul; 352(7):e1800376. PubMed ID: 31215674
[TBL] [Abstract][Full Text] [Related]
10. Functionalized N(2-oxyiminoethyl) piperazinyl quinolones as new cytotoxic agents.
Rajabalian S; Foroumadi A; Shafiee A; Emami S
J Pharm Pharm Sci; 2007; 10(2):153-8. PubMed ID: 17706174
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches.
Hu W; Huang XS; Wu JF; Yang L; Zheng YT; Shen YM; Li ZY; Li X
J Med Chem; 2018 Oct; 61(20):8947-8980. PubMed ID: 29870668
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 2-phenol-4-chlorophenyl-6-aryl pyridines as topoisomerase II inhibitors and cytotoxic agents.
Thapa P; Kadayat TM; Park S; Shin S; Thapa Magar TB; Bist G; Shrestha A; Na Y; Kwon Y; Lee ES
Bioorg Chem; 2016 Jun; 66():145-59. PubMed ID: 27174797
[TBL] [Abstract][Full Text] [Related]
13. Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases.
Singh S; Pandey VP; Yadav K; Yadav A; Dwivedi UN
Curr Protein Pept Sci; 2020; 21(11):1103-1142. PubMed ID: 32951576
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of 3,5-substituted 1,2,4-oxadiazoles as catalytic inhibitors of human DNA topoisomerase IIα.
Loboda KB; Valjavec K; Štampar M; Wolber G; Žegura B; Filipič M; Dolenc MS; Perdih A
Bioorg Chem; 2020 Jun; 99():103828. PubMed ID: 32315896
[TBL] [Abstract][Full Text] [Related]
16. Role of the Water-Metal Ion Bridge in Quinolone Interactions with
Carter HE; Wildman B; Schwanz HA; Kerns RJ; Aldred KJ
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769202
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase IV is a target of quinolones in Escherichia coli.
Khodursky AB; Zechiedrich EL; Cozzarelli NR
Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11801-5. PubMed ID: 8524852
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast.
Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1992 Jul; 267(19):13150-3. PubMed ID: 1320012
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the discovery and development of quinolones and analogs as antitumor agents.
Xia Y; Yang ZY; Morris-Natschke SL; Lee KH
Curr Med Chem; 1999 Mar; 6(3):179-94. PubMed ID: 10219099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
